| Form of release | Blister (25 tablets), Pack (100 tablets) |
|---|---|
| International Name | Ibutamoren (MK-677) |
| Chemical Name | (R)-1′-(2-methylalanyl)-N-(1-methyl-2-pyrrolidinylmethyl)-2-oxo-1H-indole-3-carboxamide |
| Type of Drug Combination | Selective agonist of ghrelin receptors (GHSR-1a), growth hormone secretagogue (GH Secretagogue) |
| Molecular Formula | C27H36N4O5S |
| Molecular Weight | 528.66 g/mol |
| Halflife | 20–24 hours, 20–24 hours |
| Mechanism of Action | Activates ghrelin receptors and stimulates the production of growth hormone (GH) and IGF-1 without affecting cortisol or prolactin levels. |
| Anabolic Activity | Indirect |
| Androgenic Activity | No |
| Main Effects | Increased secretion of GH and IGF-1, improved sleep, appetite, recovery, increased bone density, accelerated tissue regeneration, improved skin and hair condition |
| Side Effects | Increased appetite, mild water retention, possible numbness in the limbs, increased sugar levels and insulin resistance with prolonged use |
| thenecessityofpct | No, No |
| Recommended Dosage | 10–25 mg per day |
| Course Duration | 6–12 weeks |
| Reception Hours | Once a day, preferably before bedtime |
| Impact on Estrogens | No |
| Impact on the Liver | No |
| Storage | In a dry, cool place, protected from light, at a temperature not exceeding 25°C, In a dry, cool place, protected from light, at a temperature not exceeding 25°C |
| Use by Women | Safe in doses of 5–10 mg per day, improves skin, sleep, and recovery |
| Detection Period in the body | Up to 3–4 weeks |
